Аутоиммунная панель 10 антигенов (AMA M2, SP100, gp210, LKM1, LC1, CENP-B, GBM, PR3, MPO, SLA/LP)

The Autoimmune Liver Disease Antibody Panel (IgG), immunoblot method, evaluates antibodies to SLA/LP, LC-1, LKM-1, AMA-M2 (PDC/M2-3E), Sp100, PML, and gp210 to support the diagnosis and differential diagnosis of autoimmune liver disorders. This panel aids in distinguishing autoimmune hepatitis (types 1 and 2), primary biliary cirrhosis, primary sclerosing cholangitis, and overlap syndromes, and is useful when first-line markers such as antinuclear antibodies and smooth muscle antibodies are negative. Antibodies to LKM-1, LC-1, and SLA/LP help characterize autoimmune hepatitis phenotypes, whereas AMA-M2 and nuclear dot/ pore complex antibodies (Sp100, gp210, PML) support primary biliary cirrhosis. Antibody levels, particularly anti-LKM-1, may decline with treatment and can be followed to reflect disease activity, recognizing that absence of a single antibody does not exclude disease.

Autoimmune liver diseases comprise disorders in which autoantibodies directed against cellular or tissue antigens are detectable in serum. Major categories include autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and overlap syndromes. Autoantibody profiles serve as key laboratory criteria in these conditions. In AIH, patients commonly exhibit fatigue, myalgia, arthralgia, and intermittent fever, and laboratory evaluation often shows hypergammaglobulinemia or increased IgG together with disease‑specific autoantibodies. Antibodies to liver–kidney microsomes type 1 (anti‑LKM‑1) recognize cytochrome P450 2D6 and occur in approximately 15% of AIH overall, with high prevalence in AIH type 2 (about 90%). AIH type 2 typically affects children, occurs more often in girls than boys, and carries a less favorable prognosis than types 1 and 3. Anti‑LKM‑1 can also be detected in roughly 5% of patients with hepatitis C virus infection. Detection of LKM‑1 is not pathognomonic, and a negative result does not exclude AIH; comprehensive clinical and laboratory evaluation remains essential. Anti‑LKM‑1 titers may decline with effective therapy and can be used to follow disease activity. Antibodies to cytosolic antigen LC‑1 target formiminotransferase cyclodeaminase and are present in 25%–40% of patients with LKM‑1–positive AIH type 2; isolated anti‑LC‑1 occurs in about 10% of such cases and is uncommon in hepatitis C and AIH type 1. Antibodies to soluble liver antigen/liver–pancreas (SLA/LP) bind a cytosolic selenocysteine‑containing enzyme (SepSecS). They are detected in ~15% of AIH and serve as a laboratory marker in ~35% of AIH cases lacking classical markers. Anti‑SLA/LP shows high specificity for AIH type 1, but may rarely (up to 4%) be found in AIH type 2, PBC, PSC, celiac disease, and even in healthy individuals. Antimitochondrial antibodies to the pyruvate dehydrogenase complex, M2 antigen (AMA‑M2; PDC/M2), are present in 90%–95% of patients with primary biliary cirrhosis. PBC is a chronic autoimmune cholestatic disease characterized by immune‑mediated inflammation and destruction of small- to medium‑sized intrahepatic bile ducts. Patients may demonstrate hepatosplenomegaly, marked fatigue, pruritus, and jaundice, and a rise in liver enzymes, often with alkaline phosphatase as the earliest abnormality. Low‑level AMA‑M2 reactivity can occur in chronic active hepatitis, autoimmune hepatitis, and in other autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, and systemic sclerosis, reflecting an increased risk for PBC in these settings. The panel uses immunoblotting with recombinant or well‑characterized antigens, enabling simultaneous detection of multiple autoantibodies (SLA/LP, LC‑1, LKM‑1, AMA‑M2/PDC‑M2‑3E, Sp100, PML, gp210, and related targets such as Ro‑52). Antibody profiles can evolve over the disease course and with treatment, and results may be influenced by the presence of additional autoantibodies or by medication exposure. Absence of LKM‑1 does not rule out autoimmune hepatitis. When PBC is suspected, AMA testing should be interpreted alongside liver enzyme activity and direct bilirubin, and liver biopsy may be warranted for diagnostic clarification.